Entropy Technologies LP Acquires New Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Entropy Technologies LP acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 4,200 shares of the medical research company’s stock, valued at approximately $1,405,000.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Bio-Rad Laboratories by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 2,421,334 shares of the medical research company’s stock worth $837,467,000 after purchasing an additional 31,445 shares in the last quarter. Van ECK Associates Corp boosted its position in Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after purchasing an additional 644,530 shares in the last quarter. Select Equity Group L.P. boosted its position in Bio-Rad Laboratories by 26.2% in the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after purchasing an additional 134,856 shares in the last quarter. First Eagle Investment Management LLC boosted its position in Bio-Rad Laboratories by 32,296.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after purchasing an additional 634,311 shares in the last quarter. Finally, Earnest Partners LLC boosted its position in Bio-Rad Laboratories by 17.8% in the 2nd quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company’s stock worth $165,720,000 after purchasing an additional 91,882 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Citigroup increased their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada increased their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $391.80.

Bio-Rad Laboratories Stock Down 0.4 %

NYSE BIO opened at $363.20 on Thursday. The business has a fifty day moving average price of $340.33 and a 200 day moving average price of $313.52. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The company has a market cap of $10.17 billion, a P/E ratio of -13.29 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same period in the prior year, the company earned $2.33 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.